Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5586_Библиотеки_им_академика_М_И_Перельмана.pdf
Introduction to Pharmaceutical Biotechnology, Volume 2 (Second Edition)
more comprehensive representation of these intricate systems [95]. Multiscale
modeling is emerging as a significant discipline within computational biomedicine.
While numerous promising multiscale models are in existence and are currently
under development, it is worth noting the need for a unified multiscale modeling
methodology, indicating a potential area for further research and development to
enhance the multiscale modeling foundation [96].
9.5.11 Computational genomics
Computational genomics is a field that utilizes computational and statistical
techniques to deduce biological information from genomic data. With the advent
of high-throughput sequencing technologies, there has been an exponential increase
in genomic data available, necessitating the development of computational methods
to analyze this data effectively. In the field of genomics, various essential processes
and techniques are employed for data handling and analysis. Database construction
and management involve creating and maintaining databases to store, organize, and
manage genomic data efficiently. Data retrieval systems are developed to facilitate
the swift retrieval of data from these genomic databases. Sequence alignment
techniques are crucial in aligning DNA, RNA, or protein sequences to pinpoint
regions of similarity. Methods for detecting motifs and domains are used to locate
regions of DNA or RNA that are conserved. Prediction of 3D structures is a
computer approach for predicting the 3D structures of proteins and nucleic acids.
Structural elements are assigned biological roles based on their 3D structures using
the functional annotation of structural elements. One may create phylogenetic trees
showing evolutionary links between different species using phylogenetic analysis. To
understand evolutionary linkages and processes, molecular evolutionary analysis
examines molecular sequences. Genome-wide association studies (GWAS) use
statistical methods to find gene variations linked to certain diseases. This information may then be used to understand the underlying biology of such conditions
better. Biological consequences may be predicted with the help of predictive models
generated using ML algorithms from genetic data. Deep learning techniques are
used to examine large genetic datasets and discover hidden patterns and correlations
[97]. Essential for controling gene expression, regulatory elements are the subject of
regulatory element identification. These elements include promoters, enhancers, and
silencers. Building and analyzing regulatory networks to learn more about how
genes are controlled is the goal of regulatory network construction. Understanding
DNA methylation and histone modifications, two examples of epigenetic marks may
be gained by the computational process known as epigenetic mark identification. In
order to analyze the effects of gene regulation on cellular processes, it is necessary to
combine genomic and transcriptomic data with epigenetic data [98].
9.5.12 Functional genomics
The goal of functional genomics is to determine how genetics affects behavior.
Methods from several disciplines are used to show the complete process of how
genes function in living organisms. When we talk about sequencing, we mean doing
9-23
Introduction to Pharmaceutical Biotechnology, Volume 2 (Second Edition)
a whole-genome sequence from scratch [99]. In order to find variants in a genome
that has previously been sequenced, genome resequencing is used. Pan-genomic
analyses take into account all of a species or a set of related species’ genomic
information, which helps to understand the functional components and evolutionary
dynamics of the genomes [99]. The RNA-seq and metabolomics analyses cover the
RNA-seq which is utilized for transcriptome profiling to determine the continuously
altering cellular transcriptome. Metabolomics provides a more comprehensive
picture of the organism’s metabolic profile by analyzing all of the substrates and
metabolites in a biological sample. Uncovering the molecular pathways that
underlie different biological activities requires a thorough knowledge of novel genes,
including their roles and interactions [99, 100].
9.5.13 Comparative genomics
Genomes from various species are analyzed and compared as part of comparative
genomics. Comparative genomics uses principles of structure, function, and genomic
evolution. Understanding gene function and evolution is aided by gene family
analyses, which look at the evolution and function of gene families across many
species. Genomic data from different plant species may be compared using plant
evolutionary analyses, which can reveal hidden connections and histories between
them [101]. Gene evolution and function may be better understood when orthologs
and paralogs are identified and compared across species and within genomes,
respectively. Understanding the evolution and function of genomes depends on
the identification of conserved areas within genomes, which is made possible by the
use of colinearity analysis in comparative genomics [102].
9.5.14 Epigenomics
Epigenomics explores modifications of genetic materials and associated proteins,
affecting gene expression without altering the DNA sequence. It influences highthroughput technologies to map the epigenome, enhancing understanding of different genomic outputs [103]. Single-cell epigenomics focused on understanding noncoding disease-associated human variants, single-cell epigenomics provides detailed
maps of candidate cis-regulatory elements in heterogeneous human tissues, aiding in
interpreting the genetic basis of common traits and diseases [103, 104]. Highthroughput technologies have propelled epigenomics into a multi-omics era, where
powerful tools describe and record diverse layers of genomic output, allowing for a
thorough interrogation of cellular components [104].
9.5.15 Metagenomics
Metagenomics encompasses the analysis of genetic material directly sourced from
environmental samples, extending the scope of microbial genomics beyond
cultured organisms [105]. In the field of metagenomics, two fundamental methodologies play a pivotal role in understanding microbial communities—marker gene
studies and whole-genome shotgun (WGS) metagenomics. These approaches are
the foundation of our understanding of diverse ecosystems. Marker gene studies
9-24
Introduction to Pharmaceutical Biotechnology, Volume 2 (Second Edition)
focus on specific genes, often 16S ribosomal RNA genes, to provide insights into
the taxonomic composition of microbial communities. Conversely, WGS metagenomics takes a comprehensive approach, searching through the entire genomic
material present within a sample, offering a comprehensive snapshot of microbial
diversity and potential functional capabilities. These methods, while distinct, work
together to enhance our com prehen sion of microbial ecosystems [106].
Metagenomics empowered by NGS, has brought significant advancements in
our ability to investigate this complex ecosystem. The gut microbiome exerts a
profound influence on host health, and metagenomi cs provides us with the tool s
needed to interpret its role with unprecedented precision. By decoding the genetic
makeup of the many microorganisms residing within our intestines, we gain
valuable insights into their functional contributions to processes such as digestion,
metabolism, and even immune system modulation. This novel understanding not
only deepens our appreciation of the gut microbiome’ssignificance but also paves
the way for novel therapeutic interventions aimed at maintaining and restoring the
delicate balance within this microbial community, ultimately boosting host health
and well-being [107].
9.6 Bioinformatics in precision medicine
Bioinformatics plays a pivotal role in precision medicine, which aims to tailor
medical treatment to individual characteristics of each patient. It is an interdisciplinary fi eld that utilizes bioinformatics to analyze molecular data to identify genetic,
epigenomic, and other molecular predictors of drug response and disease susceptibility. Genomic medicine is an emerging medical discipline that involves using
genomic information about an individual as part of their clinical care and the health
outcomes and policy implications of that clinical use. Pharmacogenomics is a crucial
part of genomic medicine and precision medicine at large. It is the study of how
genes affect a person’s response to drugs. This field aims to develop rational means
to optimize drug therapy, with respect to the patient’s genotype, to ensure maximum
efficacy with minimal adverse effects. By understanding an individual’s genetic
makeup, doctors can prescribe medications and doses personalized to the genetic
profile of the individual [108, 109]. For instance, pharmacogenomics helps in
predicting drug dose, like the dose of thiopurines based on variation in the
thiopurine methyltransferase (TPMT). Despite its potential, the understanding of
pharmacogenomic guidelines in clinical practice has been slow but is gradually
improving. Genomic predictors of disease refer to genetic variants or patterns that
are associated with the risk of developing particular diseases. Bioinformatics tools
and techniques are employed to analyze large datasets to identify these predictors
which can then be used for risk assessment, early detection, or personalized
treatment plans. Genomic counseling extends beyond traditional genetic counseling
to encompass a broader range of genetic and genomic information. It involves
discussing with individuals or families about their genomic information and what it
means for their health, disease risk, and other life aspects [110]. Key points in
genomic counseling include:
9-25
Introduction to Pharmaceutical Biotechnology, Volume 2 (Second Edition)
• The number and/or type of diseases for which testing is available and
discussed.
• The purpose of testing.
• Intervention and clinical utility.
• Access to testing [111].
• Transition from traditional genetic counseling to genomic counseling involves
a move from reactive genetic testing for diagnosis of primarily single-gene
diseases to proactive genome-based testing for multiple conditions [111].
Personal genomics pertains to the use of genomic information at an individual level
to guide healthcare decisions includes:
• Advanced diagnostics.
• Tumor profiling.
• Genomic risk assessments [112].
Personal genomics has the potential to signifi cantly influence healthcare by enabling
personalized medicine, which tailors medical interventions to an individual’s unique
genomic profile. It is also a subject of genomics education, emphasizing the
importance and benefits of understanding personal genomic information in society,
including in classrooms, clinics, and the public sphere [113].
9.7 Translational bioinformatics
Translational bioinformatics (TBI) is a crucial field that bridges the gap between
biomedical data science and informatics, determined for a seamless translation of
scientific discoveries into clinical practice. TBI is in the forefront in areas like the
clinical utility of polygenic risk scores, data integration, and using artificial
intelligence (AI) and ML for enhanced healthcare delivery [114]. Clinical decision
support systems (CDSSs) are integral tools in TBI that assist healthcare professionals in making informed clinical decisions. They analyze data from various
sources to provide evidence-based recommendations tailored to individual patient
conditions. By integrating with electronic health records (EHRs), these systems
ensure a seamless flow of patient data, thereby facilitating better clinical decisions,
improving patient outcomes, and reducing healthcare costs. The integration of
EHRs is central to TBI as it facilitates the utilization of rich patient data for better
clinical decision-making. By convoluting EHRs with clinical decision support,
healthcare differences can be addressed more effectively, especially in low-resource
settings, thereby improving health equity [115]. Moreover, the real-world integration
of genomic data into EHRs is an effort to operationalize guidelines for precision
medicine delivery, enhancing the EHR’s capability for such advanced healthcare
provision. A significant aspect of a CDSS is its integration or interoperability with
EHRs to enhance healthcare for populations facing discrepancies. This integration
facilitates the seamless flow of patient-specific information, enabling personalized
clinical recommendations. Various studies have been conducted on clinicians facing
CDSS integrated or interoperable with EHR, revealing that most of these were
9-26
Introduction to Pharmaceutical Biotechnology, Volume 2 (Second Edition)
implemented in primary care outpatient settings for screening or treatment purposes.
The types of clinical decision support (CDS) tools include point-of-care alerts, order
facilitators, workflow support, relevant information display, expert systems, and
medication dosing support. The potential of CDS tools lies in improving health
equity and outcomes, especially for patients who face disparities. The user-centered
design is crucial during the planning, development, and implementation phases of
CDSS. It ensures that the system is adapted to meet the needs and preferences of its
users, thereby enhancing its usability and effectiveness. Implementation strategies
most frequently employed include education and consensus facilitation, which are
vital for the successful deployment and adoption of CDSSs [115].
Patient stratification is a crucial process in personalized medicine, which involves
categorizing patients into different subgroups based on their risk of developing
certain medical conditions or their response to specific treatments. This process aids
in tailoring medical treatment to individual patients or groups of patients, thereby
enhancing the effectiveness and efficiency of healthcare delivery [116]. ML models
play a significant role in patient risk stratification by predicting future disease states
based on a patient’s current clinical state and historical data. These models can help
identify which applications of predictions will be sound by distinguishing between
predictions based on physician behavior and those based on a constant representation of patient physiology [117]. Disease modeling is essential for understanding the
dynamics of disease spread and the impact of various factors on disease outcomes. It
is a multidimensional approach encompassing biological, social, and behavioral
factors. The integration of social and behavioral dynamics in disease models is
particularly significant as it influences the emergence, spread, and containment of
diseases. Recent global health threats like the Ebola and COVID-19 pandemics have
highlighted the importance of developing disease models that incorporate these
dynamics for more effective response measures and policies [118]. Disease modeling
makes use of a wide range of approaches, including computational systems biology
and the creation of patient-specific cell lines from induced pluripotent stem cells
(iPSCs), to highlight on disease causes, medication responses, and prospective
therapeutic treatments [119, 120].
9.8 Bioinformatics in drug discovery and development
The field of bioinformatics has become more important in the creation of new
medicines in recent years. It has several uses and is a major factor in the success of
modern drug research. Understanding the molecular basis of diseases and therapeutic targets requires the management and analysis of massive volumes of
biological data produced by fields such as genomics, transcriptomics, proteomics,
population genetics, and molecular phylogenetics [121]. Predictive models may be
developed to understand the behavior of bioactive chemicals using bioinformatics
tools and methodologies, which can help in the design and development of novel
medications. Bioinformatics can anticipate interactions between medications and
proteins, examine the influence on biological processes and activities, and uncover
genetic variations that may modify drug response. This is critical for comprehending
9-27
Introduction to Pharmaceutical Biotechnology, Volume 2 (Second Edition)
the workings of possible medications and their side effects [122]. Bioinformatics may
greatly speed up drug target selection, drug candidate screening, and refinement
despite the difficulties involved in drug development. This helps to overcome the
lengthy and costly nature of conventional drug discovery procedures [123]. Potential
targets must successfully move from the discovery stage to clinical trials and
ultimately the market, and bioinformatics plays a critical role in this process by
assisting with the prediction, analysis, or interpretation of clinical data. To better
understand and solve problems in drug discovery and development, chemoinformatics, combines chemistry and computer science. To better comprehend chemical
characteristics and molecular interactions in biological systems, it uses computational methods to examine chemical data. When it comes to the computer study of
molecules, molecular representation plays a crucial role by providing a means for the
systematic storage and retrieval of chemical data in both 2D and 3D formats.
Chemical databases are mined for relevant patterns and insights using data mining
methods such structural similarity matrices, classification algorithms, and descriptor
computations. Additionally, chemoinformatics and quantitative structure–activity
relationship (QSAR) modeling work in combination to improve molecular design
prediction modeling and provide insightful information about the behavior of
bioactive substances. Together, these fundamental applications enhance our knowledge of chemical structures and how they interact, advancing materials research and
medication development. Chemoinformatics supports the production of comprehensive databases, predictive models, and analytical tools required for current drug
discovery procedures, expediting the journey from molecular idea to drug development [124].
New therapeutic indications for previously authorized or experimental medications may be found via a process known as drug repositioning, repurposing,
redirecting, or reprofiling. Because of the high prices, severe hazards, and poor
speed of conventional drug development techniques, this method is gaining popularity. A crucial component of pharmaceutical research is drug repositioning, which
entails a number of essential components. In this process, computational techniques
play a key role by analyzing current data to find novel potential uses for wellestablished medications. These methods use ML and computational tools to find
correlations between medications and diseases based on chemical, genomic, or
phenotypic data. In addition, drug repositioning is well-known for its financial
viability, as it provides a cost-effective alternative to conventional drug discovery by
making use of already-existing data and resources, thus shortening the time and
lowering the costs normally associated with bringing drugs to market [125].
In the early phases of drug development, virtual screening (VS) is used to filter
through chemical libraries in search of structures with the highest propensity to bind
to therapeutic targets. It is crucial for cutting down on the time and money needed to
find potential medication candidates. Consensus virtual screening (CVS) is a recent
development in SBVS (structure-based virtual screening) with the goal of improving
SBVS accuracy and decreasing false positives in these kinds of research. Having
access to the 3D structure of the target protein is necessary for SBVS to be used. The
process of predicting drug–target interactions (DTIs) is a cornerstone of the
9-28
Introduction to Pharmaceutical Biotechnology, Volume 2 (Second Edition)
pharmaceutical industry. Drug mechanism of action, impact prediction, and side
effect avoidance all rely on this process of discovering possible drug interactions with
biological targets. Predicting DTIs is important for several reasons in the pharmaceutical industry, including virtual screening, drug repurposing, and the detection of
adverse drug reactions. It has been reported that using deep learning and ML models
in virtual screening might enhance DTI prediction, emphasizing the use of computational methods in contemporary drug development procedures [126].
9.8.1 Artificial intelligence (AI) and machine learning in bioinformatics
The use of deep learning, a type of ML and AI, in the analysis of big biological data,
prediction, and the discovery of new biological insights has shown great promise in
bioinformatics. The analysis of sequences, the identification of motifs, and the
prediction of the function or structure of molecules have all been performed using
deep learning models like CNNs and RNNs. Understanding the function of proteins
and other biomolecules requires knowing their 3D structures, which may be
predicted. Predicting molecular structures using deep learning, and in particular
CNNs, has led to significant advances in the field, with tools like AlphaFold
highlighting the potential of deep learning in structural biology. Learning how genes
work and what influences their expression, such as epigenetics, is made easier with
the help of deep learning. Deep learning may be used to investigate massive genomic
datasets in order to better understand the regulatory networks that govern cellular
activity. Deep learning aids in the comprehension of complex biological systems by
combining data at many biological scales. Multi-omics analysis, which involves
characterizing and quantifying groups of biological molecules, falls under this
category [127]. Different methods used in AI are listed in figure 9.6.
9.8.2 AI-driven drug discovery
Modern drug development procedures greatly benefit from AI, especially ML and
deep learning, which speed up the conversion of data into useful ideas. Big datasets
of chemical substances may be processed by AI algorithms, which can then forecast
their possible toxicity and effectiveness. This speeds up the drug development
process’s first screening step considerably. With the analysis of vast datasets, AI
may discover novel therapeutic applications for already-approved medications and
potentially connect pharmacological mechanisms with disease pathways. For
pharmaceuticals to be safe, it is essential to anticipate how they may interact with
one another or with diseases. AI may help in the creation of safer medications by
analyzing large, complicated information to predict potential interactions. The
identification of biomarkers is essential for tracking the effectiveness of treatments
and making diagnosis. AI can select through massive biological datasets to uncover
potential biomarkers. AI can help design more efficient clinical trials, predict
outcomes, and identify the most suitable candidates for trials. These speed up the
drug development process and bring new therapies to patients faster. Predictive
modeling encompasses a variety of statistical and ML techniques to predict
outcomes based on data. It is a crucial tool in bioinformatics and drug discovery,
9-29
Introduction to Pharmaceutical Biotechnology, Volume 2 (Second Edition)
Figure 9.6. Commonly employed machine learning algorithms in bioinformatics investigations are outlined.
Each algorithm is accompanied by an example of its application and the corresponding input data, as depicted
on the right side. Abbreviations include SVM for support vector machines, KNN for K-nearest neighbors,
CNN for convolutional neural networks, RNN for recurrent neural networks, PCA for principal component
analysis, t-SNE for t-distributed stochastic neighbor embedding, and NMF for non-negative matrix
factorization. Reproduced from [
128] CC BY 4.0.
where it enables the forecasting of biological and chemical phenomena based on
existing data [129]. Regression analysis is used to predict continuous outcomes. For
instance, it can be used to predict the binding affinity of a drug to a particular target
based on certain molecular descriptors. Classification techniques are used to predict
categorical outcomes. In bioinformatics, it might be used to classify genes into
different functional categories based on expression data. Time-series analysis can
predict outcomes over time, essential in studying biological processes that change
9-30
Introduction to Pharmaceutical Biotechnology, Volume 2 (Second Edition)
over time like cell growth or gene expression levels over a developmental timeline.
Essential for handling high-dimensional data common in bioinformatics and drug
discovery. It identifies the most informative features or reduces the dimensionality of
the data without losing essential information, and ensures the reliability and
robustness of predictive models through techniques like cross-validation [130].
Advancements in AI, particularly deep learning, have significantly impacted
image analysis and microscopy in biological research, enabling automated and more
accurate analysis. Deep learning algorithms, especially CNNs, have empowered
automated image segmentation, object detection, and classification in biological and
medical imaging. Deep learning can enhance the resolution of microscopy images
through super-resolution techniques, enabling finer examination of biological
structures. Analyzing time-lapse microscopy images using AI can reveal dynamic
biological processes, tracking cells and understanding cellular dynamics over time.
High-content screening (HCS) often involves analyzing large sets of microscopy
images to understand cellular phenotypes. AI accelerates this analysis, identifying
phenotypic changes in response to various treatments. 3D image analysis is crucial
for understanding complex biological structures. Deep learning algorithms can
segment, classify, and analyze 3D images, providing insights into 3D cellular
structures and tissues. Comprehensive understanding of biological processes may
be gained by combining data from several imaging modalities or picture data with
other forms of data (such as genomic data) [131].
9.9 CRISPR and genome editing in bioinformatics
Genome editing has been given a major boost by the CRISPR-Cas (Clustered
Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins)
technology. Bioinformatics’ ability to streamline the planning, analysis, and
interpretation of studies is crucial to expanding and directing CRISPR-Cas
applications. Designing good guide RNAs (gRNAs) is critical for efficient
CRISPR-Cas genome editing. In order to pick gRNA sequences with optimal ontarget activity and minimal off-target effects, bioinformatics methods are useful.
Using sequence similarity and other genetic markers, bioinformatics systems may
identify probable off-target regions. Algorithms and ML models have been created
to predict the on-target effectiveness of gRNAs, facilitating in the selection of the
most successful gRNAs for genome editing. Numerous options for genome editing
are made possible by the variety of CRISPR-Cas systems [132]. Bioinformatics aids
in defining and cataloging these variations, understanding their causes, and
predicting their genome-editing capabilities. The collection of data from CRISPRCas research has led to the formation of databases and libraries. These tools are
useful for the community, allowing the exchange of gRNA sequences, efficiency
ratings, and off-target predictions. Genes implicated in certain traits may be
discovered using CRISPR screening. The high-throughput data produced by these
screens, the identification of relevant hits, and the interpretation of the findings all
need the use of bioinformatics tools. The integration of CRISPR-Cas bioinformatics
tools with other bioinformatics resources may give more complete insights. The
9-31
Introduction to Pharmaceutical Biotechnology, Volume 2 (Second Edition)
whole extent to which genome editing affects biological processes, for instance, may
be shown by integrating data on genome editing with those on gene expression,
proteomics, or pathway analysis [133].
Computational tools are essential in genome editing because they guarantee
accuracy and productivity of the editing procedure. The development of guide
RNAs (gRNAs), the anticipation of off-target effects, and the analysis of genome
editing experiment results. Software tools like CRISPR Design and Benchling aid in
designing gRNAs with high on-target efficiency and minimal off-target effects. They
often provide a user-friendly interface for selecting target sequences and designing
gRNAs. Tools like Cas-OFFinder and CRISPRscan help in predicting potential offtarget sites based on sequence similarity, aiding in the design of gRNAs with higher
specificity. Certain tools offer predictions on the efficiency of designed gRNAs,
integrating factors like sequence composition and genomic context to provide a
score indicative of the likely editing efficiency. For projects requiring multiplexed
editing, tools that assist in designing multiple gRNAs and organizing complex
editing strategies are crucial.
Genome editing, especially in the context of human genomes, brings out plenty of
ethical considerations. Editing the germline potentially alters the genetic makeup of
future generations, raising concerns about unintended consequences and the ethics
of altering human evolution. Obtaining informed consent, especially in germline
editing, is a complex issue, given the long-term and often unknown implications of
genome editing. There is concern over genome editing technologies becoming a
means of extending existing social inequalities if access is restricted to affluent
individuals or communities. Establishing robust regulatory frameworks is crucial to
ensure the responsible use of genome editing technologies [134].
Functional genomics aims to understand the relationship between the genome
and the phenotype. CRISPR-based screens are powerful tools in functional
genomics. Systematically interrogating gene function on a genome-wide scale by
utilizing libraries of gRNAs targeting every gene in the genome. Following genome
editing, phenotypic changes can be assessed using a variety of assays, elucidating the
function of individual genes or gene networks. Bioinformatics tools are essential for
analyzing the vast datasets generated from CRISPR screens, identifying significant
genes, and interpreting the biological implications. Combining CRISPR screen data
with other omics data (transcriptomics and proteomics) can provide a more broader
understanding of gene function and cellular processes [135].
9.10 Integrative and multi-omics analysis
The advent of high-throughput technologies has facilitated the generation of largescale biological data across different molecular levels. Integrative and multi-omics
analyses seek to combine these data to provide a more comprehensive understanding
of biological systems. Integrative genomics aims to combine data from different
genomic datasets to elucidate the underlying genetic architectures of traits and
diseases. Integrative genomics is the harmonization of different genomic datasets,
ensuring data representation and analysis consistency. Meta-analysis techniques are
9-32